Decreased expression of miR-218 is associated with poor prognosis in patients with colorectal cancer

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 12, 2013, Pages 2904-2911

  Yu, Hong ^a   Gao, Guangzhong ^a   Jiang, Lin ^a   Guo, Lingchuan ^b   Lin, Mei ^a   Jiao, Xiao ^a   Jia, Weiguang ^a   Huang, Junxing ^a  

^a Taizhou People's Hospital   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Colorectal cancer; Expression; Microrna; Mir 218; Survival

Indexed keywords

MEMBRANE PROTEIN; MICRORNA; MIRN218 MICRORNA, HUMAN; NERVE PROTEIN; SIGNAL PEPTIDE; SLIT HOMOLOG 2 PROTEIN; SLIT3 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; CANCER STAGING; CELL DIFFERENTIATION; COLORECTAL CANCER; COLORECTAL TUMOR; DOWN REGULATION; EXPRESSION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MIR-218; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; TIME; VERY ELDERLY;

COLORECTAL CANCER; EXPRESSION; MICRORNA; MIR-218; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; COLORECTAL NEOPLASMS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MEMBRANE PROTEINS; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; NERVE TISSUE PROTEINS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84889073176     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. He J and Chen WQ. 2012 Chinese Cancer Registry Annual Report. Military Medical Science Press 2012; pp: 28-57.
3. Hill DA, Furman WL, Billups CA, Riedley SE, Cain AM, Rao BN, Pratt CB and Spunt SL. Colorectal carcinoma in childhood and adolescence: a clinicopathologic review. J Clin Oncol 2007; 25: 5808-5814.
4. Cordes KR and Srivastava D. MicroRNA regulation of cardiovascular development. Circ Res 2009; 104: 724-732.
5. Calin GA and Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
6. Shen J, Stass SA and Jiang F. MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett 2013; 329: 125-136.
7. Ulivi P, Foschi G, Mengozzi M, Scarpi E, Silvestrini R, Amadori D and Zoli W. Peripheral Blood miR-328 Expression as a Potential Biomarker for the Early Diagnosis of NSCLC. Int J Mol Sci 2013; 14: 10332-10342.
8. Chen Q, Si Q, Xiao S, Xie Q, Lin J, Wang C, Chen L, Chen Q and Wang L. Prognostic significance of serum miR-17-5p in lung cancer. Med Oncol 2013; 30: 353.
9. Volinia S and Croce CM. Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc Natl Acad Sci U S A 2013; 110: 7413-7417.
10. Lin Q, Chen T, Lin Q, Lin G, Lin J, Chen G and Guo L. Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer. J Surg Oncol 2013; 107: 767-771.
11. Gamez-Pozo A, Anton-Aparicio LM, Bayona C, Borrega P, Gallegos Sancho MI, Garcia-Dominguez R, de Portugal T, Ramos-Vazquez M, Perez-Carrion R, Bolos MV, Madero R, Sanchez-Navarro I, Fresno Vara JA and Espinosa Arranz E. MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. Neoplasia 2012; 14: 1144-1152.
12. Watson JA, Bryan K, Williams R, Popov S, Vujanic G, Coulomb A, Boccon-Gibod L, Graf N, Pritchard-Jones K and O'Sullivan M. miRNA profiles as a predictor of chemoresponsiveness in Wilms' tumor blastema. PLoS One 2013; 8: e53417.
13. Svoboda M, Sana J, Fabian P, Kocakova I, Gombosova J, Nekvindova J, Radova L, Vyzula R and Slaby O. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol 2012; 7: 195.
14. Davidson MR, Larsen JE, Yang IA, Hayward NK, Clarke BE, Duhig EE, Passmore LH, Bowman RV and Fong KM. MicroRNA-218 is deleted and downregulated in lung squamous cell carcinoma. PLoS One 2010; 5: e12560.
15. Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Uchida Y, Kawahara K, Nishiyama K, Seki N and Nakagawa M. Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. Urol Oncol 2012; 30: 434-443.
16. Song L, Huang Q, Chen K, Liu L, Lin C, Dai T, Yu C, Wu Z and Li J. miR-218 inhibits the invasive ability of glioma cells by direct downregulation of IKK-beta. Biochem Biophys Res Commun 2010; 402: 135-140.
17. Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S, Guo X, Wang B, Gang Y, Zhang Y, Li Q, Qiao T, Zhao Q, Nie Y and Fan D. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet 2010; 6: e1000879.
18. Li J, Ping Z and Ning H. MiR-218 Impairs Tumor Growth and Increases Chemo-Sensitivity to Cisplatin in Cervical Cancer. Int J Mol Sci 2012; 13: 16053-16064.
19. He X, Dong Y, Wu CW, Zhao Z, Ng SS, Chan FK, Sung JJ and Yu J. MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating BMI1 polycomb ring finger oncogene. Mol Med 2012; 18: 1491-1498.
20. Leite KR, Sousa-Canavez JM, Reis ST, Tomiyama AH, Camara-Lopes LH, Sanudo A, Antunes AA and Srougi M. Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. Urol Oncol 2011; 29: 265-269.
21. Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K, Imoto I, Omura K and Inazawa J. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res 2011; 71: 5765-5778.
22. Li BS, Zhao YL, Guo G, Li W, Zhu ED, Luo X, Mao XH, Zou QM, Yu PW, Zuo QF, Li N, Tang B, Liu KY and Xiao B. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One 2012; 7: e41629.
23. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB and Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513-10518.
24. Dickinson RE, Dallol A, Bieche I, Krex D, Morton D, Maher ER and Latif F. Epigenetic inactivation of SLIT3 and SLIT1 genes in human cancers. Br J Cancer 2004; 91: 2071-2078.
25. Shivapurkar N, Maitra A, Milchgrub S and Gazdar AF. Deletions of chromosome 4 occur early during the pathogenesis of colorectal carcinoma. Hum Pathol 2001; 32: 169-177.
26. Beggs AD, Jones A, Shepherd N, Arnaout A, Finlayson C, AbulafiAM, Morton DG, Matthews GM, Hodgson SV and Tomlinson IP. Loss of expression and promoter methylation of SLIT2 are associated with sessile serrated adenoma formation. PLoS Genet 2013; 9: e1003488.
27. Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J, Yue S, Huang SH, Xu W, Waldron J, O'Sullivan B and Liu FF. MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res 2011; 71: 2381-2391.
28. Yamamoto N, Kinoshita T, Nohata N, Itesako T, Yoshino H, Enokida H, Nakagawa M, Shozu M and Seki N. Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma. Int J Oncol 2013; 42: 1523-1532.
29. Wu DW, Cheng YW, Wang J, Chen CY and Lee H. Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. Cancer Res 2010; 70: 10392-10401.
30. Mo MH, Chen L, Fu Y, Wang W and Fu SW. Cell-free Circulating miRNA Biomarkers in Cancer. J Cancer 2012; 3: 432-448.
31. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J and Zhang CY. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
32. Chin LJ and Slack FJ. A truth serum for cancer--microRNAs have major potential as cancer biomarkers. Cell Res 2008; 18: 983-984.
33. Sun Y, Wang M, Lin G, Sun S, Li X, Qi J and Li J. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One 2012; 7: e47003.